Nothing is certain in the wake of COVID-19. As we move into “recovery,” it’s become clear that the path forward is crooked and circles back into itself. Such uncertainty is crippling as sites and sponsors prepare to take trials off hold and launch new ones. But it does not need to be. If we learned one thing from the pandemic, it’s this: ours is a resilient industry.
Think about this: As of June 2020, COVID-19 was unheard of nine months ago; now we have roughly 2,000 active trials underway, 350 of which are industry-sponsored.
Sponsors launched an unprecedented number of trials in an incredibly short period of time. Most of the COVID-19 trials we’ve been monitoring have gone from final protocol to first-patient first-visit in four weeks.
The industry also became more agile. In an evaluation of about 40 industry-sponsored trials active as of March 30, about 21% of the products were immune mediators and about 25% were antivirals. In just two months, there was a dramatic shift to about 35% of the trials being immune mediators and 24% being antivirals. Sponsors and sites took real-time information and pivoted.
This speed and agility must be--and we be...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).